Get started
Author

S Teitsson

Observed names: S. Teitsson, Siguroli Teitsson, Teitsson, Siguroli
ORCID: 0009-0001-7378-1675
Observed ORCID: 0009-0001-7378-1675
OpenAlex ID: A5080247056
Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia
2016 · Daniel Eriksson, David Goldsmith, et al. · BMC Nephrology · 104
PDF
Using Generative Artificial Intelligence in Health Economics and Outcomes Research: A Primer on Techniques and Breakthroughs
2025 · Tim Reason, Sven Klijn, et al. · PharmacoEconomics - Open · 26
PDF
Treatment Patterns and Survival Outcomes Among Androgen Receptor Pathway Inhibitor-Experienced Patients With Metastatic Castration-Resistant Prostate Cancer
2024 · Vivek Narayan, Miraj Y. Patel, et al. · Clinical Genitourinary Cancer · 10
Generative Artificial Intelligence to Automate the Adaptation of Excel Health Economic Models and Word Technical Reports
2025 · William Rawlinson, Siguroli Teitsson, et al. · Value in Health · 8
PDF
Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective
2024 · Thor-Henrik Brodtkorb, Christopher Knight, et al. · Journal of Medical Economics · 8
PDF
Cost–Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France
2020 · Bruno Bregman, Siguroli Teitsson, et al. · Dermatology and Therapy · 8
PDF
Estimating the Impact of Adjuvant Treatment With Nivolumab on Long-Term Survivorship Rates Compared With Surveillance in Muscle Invasive Urothelial Carcinoma: Mixture Cure Modeling Analyses of Disease-Free Survival From the Phase 3 CheckMate 274 Trial
2025 · Daniel M. Geynisman, Kateryna Chepynoga, et al. · Clinical Genitourinary Cancer · 6
1746P Disease-free survival (DFS) and distant metastasis-free survival (DMFS) as surrogates for overall survival (OS) in adjuvant treatment of muscle-invasive bladder cancer (MIBC)
2022 · C. Sternberg, P. Squifflet, et al. · Annals of Oncology · 6
Treatment Patterns Among Androgen Receptor Pathway Inhibitor-Experienced Patients With Metastatic Castration-Resistant Prostate Cancer: A Global Real-World Study
2026 · Gunhild von Amsberg, Alison Bulkley, et al. · Clinical Genitourinary Cancer · 4
PDF
1758P Characteristics, management and survival outcomes of French patients (pts) with muscle invasive bladder cancer (MIBC) at high risk of recurrence (MIBC-HR): A study based on the COBLAnCE cohort
2022 · A. Fraslin, F.P. Colrat, et al. · Annals of Oncology · 4
PDF
Characteristics, management and survival outcomes in patients with muscle-invasive bladder cancer at high risk of recurrence in France: a subgroup analysis from the coblance cohort
2025 · Aldéric Fraslin, Florian Colrat, et al. · BMC Urology · 2
PDF
Cost-effectiveness of nivolumab compared with surveillance for adjuvant treatment of muscle-invasive urothelial carcinoma at high risk of recurrence in France
2025 · Sylvie Negrier, Julia Bonastre, et al. · World Journal of Urology · 2
PDF
EE494 AI-Driven Virtual Assistance Interface for Excel-Based Economic Model
2024 · S Pandey, R Kaur, et al. · Value in Health · 2
PDF
EE205 Automating Economic Modeling: Potential of Generative AI for Updating Modeling Reports
2024 · W Rawlinson, S Teitsson, et al. · Value in Health · 2
PDF
P48 Automating Economic Modelling: Potential of Generative AI for Updating Excel-Based Cost-Effectiveness Models
2024 · W. Rawlinson, S. Klijn, et al. · Value in Health · 2
PDF
Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo
2024 · Siguroli Teitsson, Thor-Henrik Brodtkorb, et al. · Journal of Medical Economics · 2
PDF
1824P Treatment patterns among novel hormonal therapy-experienced patients with metastatic castration-resistant prostate cancer
2023 · V. Narayan, M. Patel, et al. · Annals of Oncology · 2
PDF
CO55 Radiographic Progression-Free Survival (RPFS) as a Surrogate Endpoint for Overall Survival (OS) in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (MCRPC): A Correlation Meta-Analysis
2022 · L Leung, M Patel, et al. · Value in Health · 2
Pcn192 Cost-effectiveness of Nivolumab for the Adjuvant Treatment of Patients With Melanoma With Involvement of Lymph Nodes or Metastatic Disease Who Have Undergone Complete Resection in Greece
2019 · M. Augusto, S. Teitsson, et al. · Value in Health · 2
PDF
P24 Innovations in Automated Survival Curve Selection and Reporting of Survival Analyses Through Generative AI
2024 · Y Wu, S Klijn, et al. · Value in Health · 1
PDF
HTA156 Assessing the Generalizability of Automating Adaptation of Excel-Based Cost-Effectiveness Models Using Generative AI
2024 · W Rawlinson, S Teitsson, et al. · Value in Health · 1
PDF
Estimating the impact of adjuvant treatment with nivolumab on long-term survivorship rates compared with surveillance: Analyses of disease-free survival (DFS) from the phase 3 CheckMate-274 trial.
2024 · Daniel M. Geynisman, Georgia Yates, et al. · Journal of Clinical Oncology · 1
PDF
CO205 Evaluating Disease-Free Survival (DFS) As a Surrogate Endpoint (SE) for Overall Survival (OS) in Muscle-Invasive Urothelial Carcinoma (MIUC): An Analysis of Surveillance, Epidemiology, and End Results (SEER)-Medicare Data
2023 · L. Leung, S. Kanters, et al. · Value in Health · 1
PDF
CO29 Post Distant Recurrence (DR) Survival of Muscle-Invasive Urothelial Carcinoma (MIUC) Patients with Prior Radical Cystectomy (RC): Analysis of a Flatiron Real-World Cohort Matched to CheckMate-274
2023 · M. Lambton, K. Nickel, et al. · Value in Health · 1
PDF
P27 The Impact of Incorporating Survival Heterogeneity into Modeling of Survival Outcomes for Patients with Muscle-Invasive Bladder Cancer after Radical Resection: Analyses from a Retrospective Real-World Study in France
2023 · K. Chepynoga, T. De, et al. · Value in Health · 1
PDF
Works count: 79
Citation count: 218
H-index: 6
I10-index: 3
Year
Topic
Type